Kornimate/medical-research-clean huggingface dataset:
explore the association between the emotion recognition and the attention processing under the emotional stimuli in adhd

Conditions: Attention Deficit/Hyperactivity Disorder

Summary: lots of studies suggest that children with adhd have deficits in facial emotion recognition, especially for the negative emotion. but there were arguments for this deficit is a secondary problem due to the general attention impairment in adhd, or a specific social cognitive processing to adhd. the objectives of this study are to investigate that association between the deficits in facial emotion recognition and the emotional attention processing in adhd. in this study, the investigators use the emotion attentional bias and emotional go / no go paradigm to answer this question.

the sample will consist of 100 children and adolescent with adhd and 100 typical controls, ages 8-16. the adhd group inclusion criteria are patients who have clinically diagnosis of dsm-iv adhd confirmed by the k-sads-e, and have iq \> 80; and whose parents consent to this study. the measurements will be included: 1. diagnostic assessment tools: * chinese version of kiddie-schedule for affective disorders and schizophrenia-epidemiology version. * conners' parent/teacher rating scale- revised: short form, cprs-r:s/ctrs-r:s. * swanson, nolan, and pelham, version ⅳ（snap-ⅳ）rating scale - parent/ teacher form. 2. emotion assessment tools: * facial emotion recognition task. * emotional attentional bias task. * emotional go/ no go task. 3. cognitive assessment tool: * wechsler intelligence scale for children-fourth edition chinese version. this study could offer the suggestion for the further intervention of social function in adhd.

Eligibility criteria:
inclusion criteria: 1. control group * the subjects without adhd. * ages range from 8 to 16 * full scale iq ≥ 80 * the subjects who and whose parents consent to this study. 2. adhd group * patients who have clinically diagnosis of dsm-iv adhd confirmed by the k-sads-e. * ages range from 8 to 16 * full scale iq ≥ 80 * patients who and whose parents consent to this study. exclusion criteria: * mental retardation * schizophrenia, schizoaffective disorder * mood disorders * organic psychosis * learning disorder * pervasive developmental disorder * the subjects of control group if have a history of the following condition as defined by dsm-iv: adhd in addition to the above exclusion criteria will be excluded.

Keywords: adhd, emotion recognition attention
the effect of exercise on quality of life, sleep quality and anxiety in patients with prediabetes (efexquls)

Conditions: PreDiabetes; Physical Inactivity; Quality of Life; Sleep; Anxiety; Depression

Summary: the aim of this study is to determine the effect of exercise on quality of life, sleep quality and anxiety in patients with prediabetes.

randomized controlled studies are needed to examine the effects of exercise on sleep quality, quality of life, anxiety and depression in patients with prediabetes. the aim of this study is to determine the effect of exercise on quality of life, sleep quality and anxiety in patients with prediabetes.

Eligibility criteria:
inclusion criteria: * 18-59 years old * living a sedentary life (physical activity below 300 kcal/day will be evaluated with the minnesota leisure physical activity questionnaire) * those who have sufficient motivation to participate in the exercise program (will be evaluated by a one-on-one interview by the researchers) * those diagnosed with prediabetes by oral glucose tolerance test and/or hba1c measurement will be included. * being eligible to participate in an exercise program after a cardiac examination (resting ecg and questioning of cardiac symptoms, advanced tests such as exercise ecg test if necessary) performed by the physician exclusion criteria: * serious medical condition (for example, advanced malignancy or major neurological, psychiatric or endocrine disease, respiratory failure, etc.) that would prevent the person from participating in exercise training. * having cardiovascular disease * being diabetic * receiving hormone replacement therapy * life expectancy less than 1 year * hiv positivity * substance use * functional dependency * cognitive weakness * those who have other diseases that will affect the results of the study (respiratory diseases, muscle diseases, etc.) * those who use drugs or supplements that will affect the results of the study

Keywords: prediabetes physical inactivity quality of life sleep anxiety depression
optic nerve sheath diameter is associated with postoperative delirium in patients undergoing open heart surgery

Conditions: Delirium, Postoperative; Cardiac Disease; Cardiac Valve Disease

Summary: although the incidence of delirium after cardiac surgery is high, it is not sufficiently recognized. the long-term effects of delirium are likely to be underestimated. in this study, the investigators aimed to examine the relationship between optic nerve sheath diameter and postoperative delirium in open hearth surgery.

postoperative delirium is characterized by widespread brain involvement and its incidence is between 6% and 30%. it appears twice as often after cardiac and vascular surgery than other types of surgery. the correlation between optic nerve sheath diameter (onsd) and invasive intracranial pressure measurement is excellent. onsd reduction has the potential to indicate intracranial hypoperfusion causing delirium. in this observational study, patients aged 18 years and over who will undergo open heart surgery will be examined. onsd will be measured using ultrasound five times in the perioperative period (t0: pre-induction, t1: post-induction, t2: onset of cardiopulmonary bypass (cpb), t3: post-cpb, and t4: post-icu admission). the confusion assessment method for the icu (cam-icu) test will be used to examine delirium in the icu. whether the change in onsd is an independent risk factor for delirium will be evaluated.

Eligibility criteria:
inclusion criteria: * ≥18 year old * elective open heart surgery exclusion criteria: * psychiatric illness * neurological disease * ophthalmic disease * previous eye surgery * perioperative cerebrovascular disease * need for postoperative intraaortic balloon or extracorporeal support system

Keywords: optic nerve sheath diameter cardiac surgery ultrasound
safety, tolerability, pharmacodynamic, efficacy, and pharmacokinetic study of dyne-251 in participants with duchenne muscular dystrophy amenable to exon 51 skipping

Conditions: Duchenne Muscular Dystrophy (DMD)

Summary: the primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (iv) doses of dyne-251 in participants with duchenne muscular dystrophy (dmd) amenable to exon 51 skipping. the study consists of 3 periods: a multiple-ascending dose (mad) / placebo-controlled period (24 weeks), an open-label period (24 weeks) and a long-term extension (lte) period (192 weeks).


Eligibility criteria:
inclusion criteria: * age 4 to 16 years inclusive, at the time of informed consent/assent. * male with a confirmed diagnosis of dmd and with a mutation in the dystrophin gene characterized by exon deletion amenable to exon 51 skipping. * upper extremity muscle group that is amenable to muscle biopsy. * brooke upper extremity scale score of 1 or 2. * ambulatory or non-ambulatory. a non-ambulatory participant must have been non-ambulatory for \<2 years before enrollment. * receiving a stable dosage of glucocorticoids for at least 12 weeks prior to the start of study drug administration, with the expectation of maintaining a stable dose during the placebo-controlled and open-label periods of the study (unless dose adjustment is required by weight change). * left ventricular ejection fraction of ≥50% by echocardiogram or ≥55% by cardiac magnetic resonance imaging (mri). exclusion criteria: * uncontrolled clinical symptoms and signs of congestive heart failure (chf). * any change in prophylaxis/treatment for chf within 3 months prior to the start of study treatment. * history of major surgical procedure within 12 weeks prior to the start of study drug administration or an expectation of a major surgical procedure during the study. * requirement of daytime ventilator assistance. * percent predicted fvc \<40 % (applies only for participants who are age ≥7 years). * receipt of eteplirsen, or alternative exon-skipping/dystrophin-modifying therapy, within 12 weeks of randomization. * receipt of non-exon skipping investigational drug within 4 months before the start of study drug administration. * receipt of gene therapy at any time. other inclusion and exclusion criteria may apply.
mediterranean diet and protein-sparing modified diet for metabolic syndrome in liver transplant recipients

Conditions: Liver Transplantation; Metabolic Syndrome X; Obesity

Summary: many metabolic complications can develop after liver transplant including: diabetes, high blood pressure, obesity, heart attacks and stroke. the goal of this study is to look at the safety and effect of 2 well known and established diet regimens on the people who had a prior liver transplant and investigate whether it helps with the control of these comorbidities.

the mediterranean diet has been shown to be effective in improving hepatic steatosis, insulin sensitivity, diabetes control and reducing cardiovascular risk in adult patients, but there is no data available for patients who underwent liver transplant. the protein-sparing modified fast (psmf) diet has been used for years at the cleveland clinic to treat adult patients with obesity-related medical problems, but its safety and efficacy has not been established in liver transplant recipients.

Eligibility criteria:
inclusion criteria: adult patients \> 18 years old who had a successful liver transplant at least 1 year prior to enrollment who also have a bmi\>30 with previous failed attempts at weight loss via conventional methods. in addition to one of the following: 1. triglyceride (tg)\>150 mg/dl or specific treatment for this lipid abnormality 2. hdl \<40 mg/dl in females and \<50 mg/dl in males or specific treatment of this lipid abnormality 3. systolic bp \>130 or diastolic bp \>85 mm hg or treatment for previously diagnosed hypertension 4. fasting plasma glucose \>100 mg/dl or previously diagnosed type 12 diabetes exclusion criteria: * significant behavioral issues that would interfere with compliance * lack of readiness to change (pre-contemplation, contemplation or preparation stages) * previous bariatric surgery * pregnant or planning to become pregnant * history of a documented eating disorder (e.g. bulimia) * history of kidney stones

Keywords: weight loss diet, mediterranean diet, reducing protein sparing modified diet
a trial for patients with advanced/recurrent cervical cancer

Conditions: Cervical Intraepithelial Neoplasia; Uterine Neoplasms; Genital Neoplasms, Female

Summary: this phase ii trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 iv over 10 minutes in patients with recurrent cervical cancer.


Eligibility criteria:
inclusion criteria: * recurrent squamous or non-squamous cell carcinoma of the cervix with documented disease progression * measurable disease * gynecologic oncology group (gog) performance status 0-2 * patients must have received one prior systemic chemotherapy for persistent or recurrent disease * patients with mild to moderate renal insufficiency should avoid taking non-steroidal anti-inflammatory drugs (nsaids_ with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of pemetrexed. * all patients taking nsaids with longer half-lives, should interrupt dosing for at least 5 days before, the day of, and 2 days following pemetrexed administration. * folic acid (350-1000 ug) must be given daily beginning approximately 5-7 days prior to first does of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. * vitamin b12 (1000 ug) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy exclusion criteria: * prior pemetrexed * patients who have received radiation to more than 25% of marrow bearing areas * any evidence of other malignancy within last 5 years, with exception of non-melanoma skin cancer
retrospective review of fdg pet mri management of patients with muscle invasive bladder cancer

Conditions: Bladder Cancer

Summary: background: bladder cancer is a common cancer in the u.s. survival rates for metastatic bladder cancer have not gotten better for 15 years. diagnosing and assessing the disease is important for treating it. the best way to tell what stage a cancer is in is computed tomography. this is also called ct. but it does not always give the best images of the bladder. adding a test called positron emission tomography (pet) can help. magnetic resonance imaging (mri) is even better than ct for detecting bladder cancer. but it is not widely used. some people with bladder cancer have already had mri/pet and ct. researchers want to study their records. they want to compare the different ways of assessing the disease. objective: to evaluate the use of mri/pet for diagnosing and treating metastatic bladder cancer. eligibility: people 18 years and older who were in studies between 2013 and 2016 design: researchers will study existing records. there will be no active participants. the records will have no data that could identify the participants. data will be stored on secure computers. no study participants will be contacted without approval from a review board.

this protocol is a chart review of the diagnostic imaging and management of patients with metastatic bladder cancer who have undergone pet mri. the study will involve only review of patient records and will not use specimens or participant contact. the participants whose records will be reviewed in this protocol were enrolled on a number of different protocols between 2013 and 2016.

Eligibility criteria:
* inclusion criteria: patients with metastatic bladder cancer seen between 2013 and 2016 at the nih clinical center. exclusion criteria: patients who opted out of storage of specimens/data for future use on prior studies will be excluded from this study.

Keywords: diagnostic imaging review of patients records pet mri treatment responses
evaluation of cardiac function in acutely decompensated cirrhosis

Conditions: Cirrhosis; Acute Liver Failure; Cardiomyopathies

Summary: this project aims to investigate cardiac function in patients with cirrhosis in the acute setting. acute decompensation and acute-on-chronic liver failure are major events in the life of a patient as they herald disease progression and negative prognosis. cardiocirculatory function will be assessed by serial assessments in patients admitted for acute decompensation of cirrhosis.

in this project we aim to investigate the dynamic role of cardiac function in the short-term evolution of patients with ad of cirrhosis through noninvasive and accessible tests and validate prognostic imaging and serum biomarkers. the main objectives are: 1. to describe changes and evolution of cardiac function in ad of cirrhosis 2. to investigate associations between echocardiographic parameters and serum biomarkers 3. to investigate the association between aclf and cardiac dysfunction 4. to assess the short-term prognostic impact of cardiac function in ad and aclf; 5. to evaluate the added predictive value of cardiac markers to current scores (clif-c).

Eligibility criteria:
inclusion criteria: * proven cirrhosis with acute decompensation exclusion criteria: * screening after \> 72 hours from admission * previous severe cardiac conditions (e.g. ischemic heart disease, atrial fibrillation, congestive heart failure, icd) * concomitant severe disease (e.g. active neoplasia, severe copd, etc) * lack of informed consent * intubated/ comatose patient
assessment of adherence to medical theraрy and its influence on long-term outcomes in patients with heart failure

Conditions: Heart Failure

Summary: the aim of this prospective cohort study is to assess the adherenсe to medical therapy and its influence on long-term outcomes in patients with chronic heart failure in the outpatient registry

registry profile is a patients database with cardiovascular diseases who consistently apply to the specialized cardiology department of the "national medical research center for preventive medicine" for consultation or to assess their possible participation in clinical trials the purpose of this study is to assess adherence to medical therapy and its impact on long-term outcomes in patients with chronic heart failure enrolled to profile registry from 01 january 2016 to 01 july 2020. the patients who were enrolled between 01 january 2016 to 01 december 2019 will be invited to clinical visit by phone. for patients who will join profile registry after 01 december 2019 the first visit of this study is the day of enrollment to profile registry. the first visit (v1) is an inclusion in the study. during this visit assess adherence to medication therapy general and to specific medications. the main factors affecting treatment adherence will be identified. the second visit (v2) is planned for each patient 1 year after the first visit (v2). during the second visit the adherence to the therapy and frequency of secondary outcome measures will be estimated. impossible to visit repeated, a telephone interview can be done

Eligibility criteria:
inclusion criteria: * all patients with documented сhronic heart failure who were included in register profile from from junuary 1, 2016 to july 31, 2020 * ejection fraction \<50% or * ejection fraction ≥ 50% plus increase of bnp\>500 ng/l or nt-probnp \ 900 ng/l; \>75years \> 1800 ng/l exclusion criteria: * patients whose life status is defined as "dead" * patients who refused to participate in our study * refusal to sign informed agreement

Keywords: chronic heart failure, adherence, registry
quadratus lumborum block after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

Conditions: Cytoreductive Surgery; Hyperthermic Intra-peritoneal Chemotherapy; Peritoneal Cancer

Summary: this study aims to assess whether transmusculr quadratus lomborum block (ql block) can reduce postoperative pain after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (crs and hipec). patients will be randomly assigned to either ql block group or control group. ultrasound-guided bilateral transmuscular quadratus lomborum block will be performed in ql block group using 0.375% ropivacaine. multimodal analgesic regimen including acetaminophen, nonsteroidal antiinflammatory drugs (nsaids), and rescue opioids will be used in every patient. primary outcome is opioid consumption for 24 hours after surgery. secondary outcomes included pain scores, time to first rescue analgesics, quality of recovery score, length of hospital stay.

adult patients scheduled to undergo cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy will be screened for eligibility. after induction of general anesthesia, ultrasound-guided bilateral transmuscular quadratus lomborum block will be done in ql block group. 0.375% ropivacaine will be injected to each side. patients in control group will receive no block. multimodal analgesia will be applied to every patient for postoperative pain control. multimodal analgesic regimen included scheduled administration of acetaminophen, nsaids, and rescue opioids. blinded investigator will assess pain scores at rest and on movement at 6, 12, 24, 48, 72 hours after surgery, analgesic consumptions, nausea, vomiting, and quality of recovery questionnaire.

Eligibility criteria:
inclusion criteria: - adult patients who are scheduled to undergo cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (crs and hipec) exclusion criteria: 1. allergy to local anesthetics or fentanyl 2. chronic pain 3. drug abuse 4. patients who are unable to use patient-controlled analgesia 5. skin infection at site for quadratus lomborum block 6. pregnant or breatfeeding women 7. patients who are unable to communicate
bone remodeling and non-surgical periodontal therapy

Conditions: Periodontal Diseases

Summary: previous studied have investigated the pathophysiological role and expression of cathepsin k (ctsk) , receptor activator of the nf-κb ligand (rankl) and periostin in active periodontitis and peri-implantitis lesions. however, the potential influence of non-surgical periodontal therapy including scaling and root planning on the bone remodeling markers level over different trial times have not well determined. thus, the current research is conducted to address this influence. thus, the research question will be: in patients with periodontitis, does the level of bone remodeling markers altered after successful nspt during different healing time periods?


Eligibility criteria:
inclusion criteria: 1. both males and females. 2. unstable periodontitis. 3. no previous periodontal treatment is conducted during the past 6 months. 4. good general health without history of any systemic diseases. 5. present with at least 20 teeth. 6. non-smokers. exclusion criteria: 1. subjects have any intraoral plaque retentive factors such as those wearing partial denture, crown and bridges, and orthodontic appliances. 2. subjects receiving antibiotic therapy during the previous 3 months. 3. pregnant or lactating women. 4. smokers. 5. not willing to participate or continue to conduct the study.
engaging informal health care providers on case detection and treatment initiation rates for tb and hiv in rural malawi (triage plus)

Conditions: Tuberculosis; HIV

Summary: the intervention consisted of training non-paid informal healthcare providers (such as store-keepers) in tb and hiv disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness. front line public health personnel and community leaders were sensitised to support the intervention.

a phased, matched, parallel cluster design was used to randomise three clusters (average population size per cluster = 200,714) to the early intervention arm (received the intervention early in the first 12 months) and an equal number to the delayed intervention arm (average population size per cluster = 209,564) which received the intervention after one year. data for impact evaluation were obtained from routine patient registers in all the health facilities and patients were blindly allocated to the respective clusters based on residential address. treatment initiation rates (expressed as incidence rate ratios) for tb and anti retroviral therapy (art) over the 12 months period were the primary outcome measures for each of the studied conditions. poisson regression models with robust standard errors were used to assess the effectiveness of the intervention.

Eligibility criteria:
inclusion criteria: * people accessing informal providers with possible tb or hiv exclusion criteria: * children * people already with a diagnosis of tb or hiv

Keywords: tb, hiv, case finding, access, informal providers